Regenxbio Announced Data from Phase 2 ALTITUDE Trial of RGX-314 for DR
Regenxbio (RGNX) announced initial data from the ongoing Phase 2 ALTITUDE™ trial of RGX-314 for the treatment of diabetic retinopathy (DR) without center-involved diabetic macular edema (CI-DME) using in-office suprachoroidal delivery.
Regenxbio is a clinical-stage biotechnology company seeking to improve lives . . .
This content is for paid subscribers.
Impacting News October 11, 2021